Neuphoria Therapeutics Total Assets 2022-2024 | NEUP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neuphoria Therapeutics total assets from 2022 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neuphoria Therapeutics total assets from 2022 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$160.1B
Vertex Pharmaceuticals (VRTX)	$123.9B
Gilead Sciences (GILD)	$122.2B
Bristol Myers Squibb (BMY)	$116.5B
CSL (CSLLY)	$82.8B
Regeneron Pharmaceuticals (REGN)	$79.3B
GSK (GSK)	$75.4B
Argenex SE (ARGX)	$40B
Alnylam Pharmaceuticals (ALNY)	$35.9B
BioNTech SE (BNTX)	$28.8B
BeiGene (ONC)	$22.4B
Biogen (BIIB)	$20.7B
Illumina (ILMN)	$19.5B
Insmed (INSM)	$14.5B
Incyte (INCY)	$14.4B
Intra-Cellular Therapies (ITCI)	$13.5B
Moderna (MRNA)	$12.9B
Genmab (GMAB)	$12.8B
Genmab (GNMSF)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.3B
Bio-Techne Corp (TECH)	$11.9B
Vaxcyte (PCVX)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.7B
Exact Sciences (EXAS)	$10B
Bio-Rad Laboratories (BIO.B)	$9.6B
Exelixis (EXEL)	$9.6B
QIAGEN (QGEN)	$9.4B
Repligen (RGEN)	$9.1B
Roivant Sciences (ROIV)	$7.9B